Financial Performance:
Revenue and Profit/Loss:
- Net Loss: The company reported a significant increase in spending from ordinary activities after tax, which is up 295% to $149,680,539 for the year ended 30 June 2024. This is a substantial increase compared to the previous year.
Net Tangible Assets:
- Per Security: The net tangible assets per security decreased from 2.74 cents in 2023 to 1.15 cents in 2024.
Operational Highlights:
Pipeline Progress:
- Imugene made significant advancements across its oncology assets, including Phase 1 and Phase 1b trials for its key products such as Azer-cel, VAXINIA, and onCARlytics.
- Azer-cel: Progress in Phase 1b trials for Diffuse Large B Cell Lymphoma (DLBCL) patients. This therapy is notable for its potential to be the first approved allogeneic CAR T cell therapy.
- VAXINIA: Early positive signals in Phase 1 trials for solid tumors, receiving FDA Fast Track Designation for bile duct cancer.
- onCARlytics: Initiation of Phase 1 trials combining oncolytic virotherapy with other treatments for advanced solid tumors.
Strategic Moves:
- Acquisition of the Azer-cel allogeneic CD19 CAR T cell therapy program from Precision Biosciences, Inc.
- Partnership with Kincell Bio for the sale of a manufacturing facility, expected to save significant operational costs.
Financial Position:
- Cash Reserves: Reduced from $153,150,662 in 2023 to $93,107,538 in 2024, reflecting increased spending on R&D and acquisitions.
- Capital Raise: Successfully raised $35 million through a placement and an additional $18.2 million via a Share Purchase Plan (SPP).
Management and Corporate Changes:
- Strengthened senior management team with new appointments, including Chief Operating Officer and Chief Medical Officer.
- Forums
- ASX - By Stock
- IMU
- Ann: Appendix 4E and Annual Report
Ann: Appendix 4E and Annual Report, page-10
-
- There are more pages in this discussion • 122 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $356.9M |
Open | High | Low | Value | Volume |
4.9¢ | 4.9¢ | 4.8¢ | $328.5K | 6.792M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
45 | 5443565 | 4.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.9¢ | 2171910 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
36 | 4613688 | 0.048 |
36 | 4066646 | 0.047 |
46 | 3070983 | 0.046 |
60 | 6170008 | 0.045 |
11 | 1951364 | 0.044 |
Price($) | Vol. | No. |
---|---|---|
0.049 | 1200533 | 2 |
0.050 | 4130537 | 15 |
0.051 | 6179811 | 13 |
0.052 | 2579418 | 10 |
0.053 | 1158504 | 8 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
IMU (ASX) Chart |